Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct 13;2(1):1-17.
doi: 10.1016/j.ncrna.2016.10.001. eCollection 2017 Mar.

Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs

Bernhard Biersack  1
Affiliations
Review

Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs

Bernhard Biersack. Noncoding RNA Res. .

Abstract

Platinum(II) complexes such as cisplatin, carboplatin and oxaliplatin are clinically approved for the therapy of various solid tumors. Challenging pathogenic properties of cancer cells and the response of cancers towards platinum-based drugs are strongly influenced by non-coding small RNA molecules, the microRNAs (miRNAs). Both increased platinum activity and formation of tumor resistance towards platinum drugs are controlled by miRNAs. This review gives an overview of the interactions between platinum-based drugs and miRNAs, and their influence on platinum activity in various cancer types is discussed.

Keywords: 5-FU, 5-fluorouracil; Anticancer drugs; CBDCA, cyclobutane-1,1-dicarboxylate; Carboplatin; Cisplatin; DACH, 1,2-diaminocyclohexane; DDP, cisplatin; EGCG, (−)-epigallocatechin-3-gallate; EOX, epirubicin/oxaliplatin/xeloda; FOLFOX, folinate/5-FU/oxaliplatin; GC, gemcitabine/cisplatin, gastric cancer; LNA, locked nucleic acid; MVAC, methotrexate/vinblastine/adriamycin/cisplatin; MicroRNA; Oxaliplatin; Platinum complexes; XELOX, xeloda/oxaliplatin; dTTP, deoxythymidine triphosphate.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Structures of the platinum(II) complexes cisplatin, carboplatin and oxaliplatin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rosenberg B., VanCamp L., Trosko J.E., Mansour V.H. Platinum compounds: a new class of potent antitumour agents. Nature. 1969;222:385–386. - PubMed
    1. Jamieson E.R., Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 1999;99:2467–2498. - PubMed
    1. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005;4:307–320. - PubMed
    1. Kartalou M., Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat. Res. Fundam. Mol. Mech. Mutagen. 2001;478:23–43. - PubMed
    1. Oh G.S., Kim H.J., Shen A., Lee S.B., Khadka D., Pandit A., So H.S. Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. Electrolyte Blood Press. 2014;12:55–65. - PMC - PubMed

LinkOut - more resources